Monograph Details
|
|
Immune System
> Immunization
|
|
VAQTA |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Hepatitis A vaccine, inactivated 25Units per 0.5mL (pediatric/adolescent), or 50Units per 1mL (adult); susp for IM inj; aluminum adsorbed; preservative-free. |
| Indications |
|
Hepatitis A immunization. |
| Children |
|
<12 months: not recommended. 1–18 yrs: 0.5mL IM at elected date and booster dose (0.5mL IM) 6–18 months later. |
| Adults |
|
≥19 yrs: 1mL IM at elected date and booster dose (1mL IM) 6–18 months later. |
| Precautions |
|
Have epinephrine (1:1000) available. Latex allergy. Inject into deltoid muscle, preferably at least 2 weeks before expected exposure. If given with immune globulin, use separate syringe and different site. Fever. Malignancies. Immunocompromised (may have suboptimal response). Bleeding disorders. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Immunosuppressives may reduce efficacy. Concomitant vaccines, immune globulins: see literature. |
| Adverse Reactions |
|
Injection site reactions (esp. pain, tenderness), headache, fever, GI upset, myalgia, abdominal pain, rash, pharyngitis and other upper respiratory tract effects. |
| How Supplied |
Prefilled syringes (0.5mL, 1mL)—1, 5
Single-dose vials (0.5mL)—1, 10
Single-dose vials (1mL)—1, 5, 10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
